Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03489226 · ClinicalTrials.gov registry record · NA
Capsimax Effect on Metabolic Rate, Satiety and Food Intake
A NA study, sponsored by Pennington Biomedical Research Center.
- Completed
- Registry status
- NA
- Development phase
- 24
- Enrollment target
NCT03489226: Completed NA study, sponsored by Pennington Biomedical Research Center.
NCT03489226 is a NA study that has completed, run by Pennington Biomedical Research Center. The registered enrollment target is 24 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03489226, a NA study, has completed, sponsored by Pennington Biomedical Research Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
Study Summary
Comparison of Capsimax™ 2mg and 4mg of capsicum extract vs. placebo on metabolic rate and satiety.
Primary Outcome
Metabolic cart measurement difference before and after intervention
Interventions
- DIETARY_SUPPLEMENT Placebo
- OTHER Meal
- DIETARY_SUPPLEMENT Capsimax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2016-05-02 |
| Est. Completion | 2017-07-12 |
| Phase | NA |
What the finished NCT03489226 record still lists
NCT03489226 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03489226 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03489226 about?
NCT03489226 is a clinical study titled "Capsimax Effect on Metabolic Rate, Satiety and Food Intake". Comparison of Capsimax™ 2mg and 4mg of capsicum extract vs. placebo on metabolic rate and satiety.
What is the current status of trial NCT03489226?
This trial is currently completed. It is a NA study. The enrollment target is 24 participants. The study started on 2016-05-02. Estimated completion is 2017-07-12.
What interventions are being tested in trial NCT03489226?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Meal (OTHER), Capsimax (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03489226?
This trial is sponsored by Pennington Biomedical Research Center, which has 258 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03489226's enrollment target sits among peer trials
24 1736th of 2000 higher than 246 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI